Patent Evergreening: Legal Methods to Extend Patent Protection

By leveraging various legal mechanisms like formulation, dosage, and use patents, along with sophisticated divisional and continuation application strategies, companies can safeguard their R&D investments and ensure market exclusivity beyond the initial patent term. This article delves into the lawful approaches to patent evergreening, providing practical insights and real-world examples.

Understanding Patent Evergreening: A Strategic Imperative

Patent evergreening refers to the practice of obtaining new patents for minor improvements, new formulations, or novel uses of an existing invention near the expiration of its original patent. While sometimes criticized by generic manufacturers and consumer advocacy groups as a tactic to delay competition, it is, in essence, a lawful exercise of intellectual property rights designed to protect significant R&D investments.

"Innovation is not a one-time event; it's a continuous process. Patent evergreening, when executed ethically and legally, reflects this reality by protecting incremental advancements that still require substantial investment and offer new benefits." - Jian Zhu

This strategy is particularly prevalent and vital in sectors with high R&D costs and lengthy development cycles, such as the pharmaceutical industry. A typical pharmaceutical product can take 10-15 years and billions of dollars to bring to market, with perhaps only 8-10 years of effective patent life remaining by the time it reaches patients. Evergreening helps recoup these monumental investments.

The Economic Rationale for Extended Protection

Consider the financial landscape:

• Average R&D Cost: A 2020 study by the Tufts Center for the Study of Drug Development estimated the average cost to develop a new prescription drug that gains market approval to be $2.6 billion (2013 dollars), or $2.8 billion (2018 dollars) when accounting for post-approval R&D.
• Success Rates: Only about 12% of drugs entering clinical trials ultimately gain FDA approval.
• Effective Patent Life: Due to the time spent in clinical trials and regulatory review, the effective patent life for a drug can be significantly shorter than the statutory 20 years from filing. This often leaves only 7-10 years of market exclusivity to recoup the multi-billion dollar investment.

These figures underscore why legal methods to extend patent protection are not merely a desire for prolonged monopoly, but often a necessity for pharmaceutical companies to remain viable and continue innovating.

Legal Avenues for Patent Evergreening

Several legitimate patent strategies allow innovators to extend the protective umbrella around their core invention. These typically involve patenting new aspects or improvements related to the original invention.

1. New Formulations and Dosages

One of the most common and effective evergreening strategies involves developing and patenting new formulations or dosage forms of an existing drug. These are not merely cosmetic changes; they often represent significant improvements in efficacy, safety, patient compliance, or delivery methods.

• Example: Omeprazole (Prilosec®) and Esomeprazole (Nexium®)

  • A classic case is AstraZeneca's Omeprazole (Prilosec®), a proton pump inhibitor. As its patent neared expiration, AstraZeneca developed Esomeprazole (Nexium®), an enantiomer of omeprazole. Esomeprazole was patented as a new chemical entity, offering improved pharmacokinetics and efficacy for some patients. This strategy successfully extended market exclusivity for a blockbuster drug.
  • Patent Data: The original Omeprazole compound patent expired around 2001. Nexium® was launched in 2001, with its own set of patents, effectively extending protection for the underlying therapeutic mechanism.

• Types of Formulation Patents:

  • Controlled-release formulations: Patented for their ability to deliver the drug over an extended period, improving patient convenience and reducing dosing frequency.
  • Fixed-dose combinations: Patented when two or more active ingredients are combined into a single dosage form, offering synergistic effects or improved patient adherence.
  • New salt forms, polymorphs, or crystalline forms: These can offer improved stability, bioavailability, or manufacturability, making them patentable if non-obvious. For instance, a new salt form might have better solubility, leading to a more effective drug delivery.

2. New Uses (Second Medical Use Patents)

Patenting new medical uses for an existing compound is another powerful evergreening strategy, particularly relevant in pharmaceuticals. This involves discovering and patenting a novel therapeutic application for a drug that was originally approved for a different condition.

• Example: Sildenafil (Viagra® and Revatio®)

  • Pfizer's sildenafil was initially developed for angina pectoris but was found to be effective for erectile dysfunction (Viagra®). Later, it was discovered to treat pulmonary arterial hypertension (Revatio®). Each new indication, if novel and non-obvious, can be patented, providing additional layers of protection.
  • Impact: This strategy allowed Pfizer to leverage a single compound for multiple high-value markets, extending its overall commercial lifespan.

• Criteria for Patentability:

  • The new use must be novel (not previously known or disclosed).
  • It must be non-obvious (not readily apparent to a person skilled in the art).
  • It must have a utility (a demonstrable therapeutic effect).

3. Process Patents

While less direct for evergreening the product itself, patenting novel and improved manufacturing processes for an existing drug can also provide a competitive edge and indirect protection. If a new process is significantly more efficient, cost-effective, or environmentally friendly, it can be a valuable asset.

• Strategic Advantage: Even if the product patent expires, competitors might struggle to produce the drug as efficiently or cost-effectively without infringing the process patent. This can deter generic entry or force licensing agreements.

4. Continuation and Divisional Application Strategies

These procedural mechanisms are crucial for maintaining and expanding patent protection over time, often forming the backbone of an effective evergreening strategy.

Continuation Applications (US Specific)

• A continuation application is a second application for the same invention claimed in a prior non-provisional application and filed before the patenting or abandonment of the prior application.
• Purpose: Allows an applicant to pursue additional claims to the same invention disclosed in the original application. This is particularly useful when:
  • The examiner allows a narrow set of claims, but the applicant believes broader claims are also patentable.
  • New insights or competitive intelligence emerge during prosecution, suggesting new claim scopes to pursue.
  • The original application was filed broadly, and specific embodiments need more tailored protection.
• Benefit: The continuation application retains the filing date of the original (parent) application for common subject matter, which is critical for novelty and non-obviousness assessments. This means protection can extend for 20 years from the original filing date, but the scope of protection can evolve and be refined over time.

Divisional Applications

• A divisional application is a later application for an independent invention "carved out" of a prior application. It is typically filed when the patent office determines that the original application contains claims directed to more than one invention (a "restriction requirement").
• Strategic Use: While often filed in response to a restriction, divisional applications can also be strategically used to:
  • Protect different aspects or embodiments of a complex invention that were initially disclosed in a single parent application.
  • Delay the examination of certain claims while others proceed, allowing for more time to develop market insights or refine claims.
• Example: A pharmaceutical patent application might initially disclose a compound, its use, and a specific formulation. If the patent office issues a restriction requirement, the applicant can file divisional applications to pursue separate patents for the compound, its use, and the formulation, each with its own examination timeline.

Continuation-in-Part (CIP) Applications (US Specific)

• A CIP application is a type of continuation application that includes new subject matter not present in the parent application.
• Strategic Use: While it gets the benefit of the parent's filing date only for the common subject matter, the new subject matter gets the CIP's filing date. This is useful for incorporating improvements or new data discovered after the initial filing but before the parent patent issues, effectively updating the patent portfolio to reflect ongoing R&D.

Case Study: The Pharmaceutical Industry's Evergreening Landscape

The pharmaceutical industry provides the most prominent examples of patent evergreening. A study published in Health Affairs in 2018 found that:

• 78% of new drug patents between 2000 and 2017 were not for new drugs but for existing ones. These included patents for new formulations, delivery methods, or new uses.
• Average Patent Extensions: These secondary patents extended the effective patent life of drugs by an average of 37 years beyond the original compound patent. While this number might seem high, it includes multiple layers of patents, each protecting a specific innovation. The actual market exclusivity for a single drug product is typically much shorter, but these layers create a "patent thicket" that deters generic entry.

"The strategic layering of patents – covering the compound, its polymorphs, formulations, dosages, and specific uses – creates a robust defense against generic challengers. It's not about creating an eternal monopoly, but about maximizing the return on a finite, high-risk investment." - Jian Zhu

Balancing Innovation and Access: The Debate

While patent evergreening is a legal and often necessary strategy for innovators, it frequently sparks debate regarding its impact on drug prices and access to affordable medicines.

• Proponents argue:

  • It incentivizes continuous innovation, even for incremental improvements that can significantly benefit patients (e.g., fewer side effects, better compliance).
  • It allows companies to recoup the enormous R&D costs, fueling future drug discovery.
  • The improvements patented are often genuinely novel and non-obvious, meeting the legal criteria for patentability.

• Critics argue:

  • It can delay the entry of lower-cost generic drugs, keeping prices high.
  • Some patents might be considered "weak" or "trivial" and primarily serve to extend market exclusivity without significant therapeutic advancement.

The legal framework for patentability (novelty, non-obviousness, utility) is designed to strike this balance. Patent offices worldwide are tasked with rigorously examining these secondary patents to ensure they meet the statutory requirements, distinguishing true innovation from mere attempts to game the system.

Conclusion

Patent evergreening, through legitimate legal methods such as patenting new formulations, dosages, uses, and leveraging strategic continuation and divisional applications, is a sophisticated and essential aspect of patent strategy, especially in industries like pharmaceuticals. It allows innovators to protect their substantial investments in research and development, ensuring a return that fuels further innovation. While the practice draws scrutiny, its foundation lies firmly within established patent law, provided the claimed inventions meet the criteria of novelty, non-obviousness, and utility. For any company seeking to maximize the value of its intellectual property, understanding and strategically employing these evergreening tactics is paramount.

Frequently Asked Questions

Q1: Is patent evergreening legal?

Yes, patent evergreening is legal. It involves obtaining new patents for new inventions or improvements related to an existing product. As long as these new inventions meet the statutory requirements for patentability (novelty, non-obviousness, and utility), they are eligible for patent protection, even if they relate to an already patented core invention. The controversy often arises from the perception of whether these new patents represent significant enough innovation to warrant extended market exclusivity.

Q2: How do continuation and divisional applications contribute to evergreening?

Continuation and divisional applications are procedural tools that allow applicants to pursue broader or different aspects of an invention disclosed in an earlier patent application.

• Continuation applications allow for the pursuit of additional claims to the same invention, often refining the scope of protection.
• Divisional applications are used to protect separate inventions that were initially disclosed in a single parent application but were deemed distinct by the patent office. Both types of applications benefit from the filing date of the original parent application for the common subject matter, allowing for a strategic evolution and expansion of the patent portfolio over time without losing priority.

Q3: What is a "patent thicket" and how does evergreening contribute to it?

A "patent thicket" refers to an overlapping set of patent rights requiring innovators to secure licenses from multiple patentees to commercialize a new product or process. Patent evergreening contributes to this by creating multiple layers of patents around a single core product – covering the original compound, various formulations, specific dosages, processing methods, and new uses. This dense web of intellectual property can make it challenging for generic manufacturers or competitors to enter the market without infringing one or more patents, effectively extending market exclusivity and deterring competition.

Q4: Are there any limitations or risks to patent evergreening?

While legal, patent evergreening is not without limitations and risks.

• Patentability Hurdles: Each new patent application must still meet strict patentability criteria (novelty, non-obviousness). Patent offices are increasingly scrutinizing "secondary" patents to ensure they represent genuine innovation.
• Legal Challenges: Evergreening strategies often face challenges from generic manufacturers who may file Abbreviated New Drug Applications (ANDAs) and seek to invalidate the later-filed patents, leading to costly and lengthy litigation.
• Public Perception and Regulatory Scrutiny: Excessive or perceived "trivial" evergreening can lead to negative public perception, accusations of anti-competitive behavior, and increased regulatory scrutiny from governments aiming to control healthcare costs.
• Cost: Prosecuting and maintaining a large portfolio of patents for a single product can be very expensive.